Browsing Tag
semaglutide
39 posts
Torrent Pharma (NSE: TORNTPHARM) enters GLP-1 market with Sembolic and Semalix as over 40 rivals chase semaglutide patent expiry windfall
Torrent Pharmaceuticals launches India's first generic oral semaglutide alongside injectable Sembolic as GLP-1 patent expires. What the pricing and strategy mean. Read more.
Novo Nordisk strengthens obesity leadership with Wegovy HD FDA approval and higher-efficacy profile
Novo Nordisk secures FDA approval for Wegovy HD, boosting weight loss efficacy. Discover what this means for the obesity drug market.
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
NATCO Pharma (NSE: NATCOPHARM) launches cheapest semaglutide in India at Rs 1,290 on Day 1 of patent expiry
NATCO Pharma launches generic semaglutide in India at INR 1,290 on Day 1 of patent expiry. What it means for GLP-1 markets. Read the full analysis.
The hidden problem with GLP-1 weight loss and Veru Inc.’s bet to fix it (NASDAQ: VERU)
Veru Inc. launches the Phase 2b PLATEAU trial combining enobosarm with semaglutide. Discover what this could mean for the $100B obesity drug market.
HIMS near 52-week low as FDA issues 30 GLP-1 warning letters
FDA sends 30 warning letters to GLP-1 compounders, targeting Hims & Hers Health (HIMS) as regulatory and legal pressure intensifies. Read what it means for investors and the sector.
EC backs higher-dose Wegovy as obesity competition intensifies
Novo Nordisk A/S wins EU approval for 7.2 mg Wegovy. Discover how this shifts obesity competition, reimbursement, and long-term strategy.
NATCO Pharma (NSE: NATCOPHARM) wins CDSCO approval for semaglutide as FDA compliance risks recede at its API unit
NATCO Pharma Limited secures CDSCO approval for semaglutide as U.S. FDA risks ease. Find out what this means for growth, execution, and investors.
Lilly’s oral GLP-1 orforglipron sustains weight loss after injectables in pivotal Phase 3 trial
Lilly’s orforglipron helped patients maintain weight loss after injectable GLP-1s in a Phase 3 trial. Find out how this could reshape obesity treatment paths.
Is dose escalation the new edge in the obesity drug war? Why GLP-1 rivals are raising the ceiling on efficacy
High-dose GLP-1 drugs like 7.2 mg Wegovy are redefining obesity treatment in 2025. Find out how dose escalation is shifting efficacy expectations.